Zhaowei Feng | Stem Cell Research | Best Researcher Award

Posted on by Cell Biologist

Dr. Zhaowei Feng | Stem Cell Research | Best Researcher Award

Dr. Zhaowei Feng, The Second Affiliated Hospital of Xuzhou Medical University, China

Zhaowei Feng is a dedicated biomedical researcher specializing in neurobiology and pharmacology, currently serving as an Assistant Researcher at The Second Affiliated Hospital of Xuzhou Medical University. With a solid academic foundation and a passion for neuroscience, Feng has made significant contributions to understanding mechanisms of neuroprotection and demyelination. His research spans neurodegenerative disease models such as multiple sclerosis and neonatal hypoxia-ischemia, utilizing molecular and cellular biology tools. Known for his collaborative nature and scientific rigor, Feng has co-authored multiple peer-reviewed articles in prestigious journals and has played pivotal roles in various national and municipal-level research projects. He is particularly recognized for co-first authorship in several studies, reflecting leadership in experimental design and data analysis. His growing influence in the field is further supported by ongoing funded projects and a research trajectory aimed at translational outcomes. Feng is committed to continuing impactful research that bridges bench science with clinical applications.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. Strong Research Focus in Neurobiology 🧠
    Zhaowei Feng has a consistent and impactful research portfolio in neurobiology, particularly in myelination, ischemia-reperfusion injury, and glutamate signaling. His work is highly relevant in addressing diseases like multiple sclerosis and neonatal hypoxia-ischemia encephalopathy.

  2. Publications in High-Impact Journals 📚
    He has co-authored several peer-reviewed journal articles in reputable journals such as Phytomedicine, Pharmacology, Oncology Reports, and Frontiers. His contributions as co-first author in multiple papers reflect significant involvement in study design and experimentation.

  3. Independent Researcher Role 🧪
    He currently serves as a Principal Investigator for a municipal-level research project funded by the Xuzhou Health Commission, demonstrating trust in his leadership and research direction.

  4. Multidisciplinary Expertise 🔬
    His research integrates pharmacology, molecular biology, and neuroscience, covering diverse mechanisms like PPARγ signaling, SUMOylation, and ferroptosis, which enhances translational potential.

  5. Rapid Academic Growth 🚀
    Transitioning quickly from a Master’s student (2019–2022) to Assistant Researcher and PI (since 2022) shows a fast-tracked academic trajectory.

⚠️ Areas for Improvement:

  1. Need for More First-Author and Corresponding-Author Papers ✍️
    While co-first authorship is commendable, a stronger emphasis on sole first or corresponding authorship in future publications would establish more scientific independence.

  2. Limited Recognition at National Level 🏅
    Most current funding and achievements are at the municipal level. Applying for national or international grants (e.g., NSFC, NIH) would elevate his research profile.

  3. Postdoctoral Training or Collaboration Abroad 🌍
    Gaining international experience or collaborating with global research centers could broaden perspectives and techniques, increasing citation impact and networking.

  4. More Diversified Research Outputs 📊
    Exploring patents, clinical trials, or translational research outcomes could further demonstrate innovation and application potential.

🎓 Education:

Zhaowei Feng began his academic journey in the biological sciences at Xuzhou Medical University, where he earned his Bachelor’s degree between 2014 and 2018. He further pursued a Master’s degree in Neurobiology at the same institution from September 2019 to July 2022. His graduate studies were marked by an intensive focus on neurodegenerative mechanisms, including demyelination and neuroinflammation, with particular attention to cuprizone-induced and ischemia-reperfusion mouse models. His research also explored glutamate transport regulation, the PPARγ pathway, and oligodendrocyte differentiation. His educational foundation not only provided him with technical proficiency in experimental neuroscience but also cultivated a strong understanding of translational biomedical research. Through rigorous coursework, laboratory experience, and thesis writing, Feng developed a robust academic profile that seamlessly transitioned into his research career. His educational journey reflects consistent dedication and a clear trajectory towards clinical and experimental neurobiology.

🧪 Experience:

Since September 2022, Zhaowei Feng has been working as an Assistant Researcher at The Second Affiliated Hospital of Xuzhou Medical University. His role involves leading preclinical studies, managing collaborative projects, and mentoring junior researchers. Feng has also served as Principal Investigator on a municipal-level research grant focusing on blood-brain barrier damage post-transplantation. He actively participates in multiple interdisciplinary studies involving neurodevelopment, myelination, and pharmacological interventions. Prior to his current role, his Master’s research provided hands-on experience with animal models, molecular techniques, and data analysis in neurobiology. Feng has authored or co-authored numerous research papers, some as co-first author, contributing significantly to study design and execution. He is also involved in translational research projects that aim to bridge laboratory findings with clinical therapies. His work ethic, attention to detail, and innovative approach make him a valuable contributor to the field of neurobiological research.

🏅 Awards and Honors:

Zhaowei Feng has been recognized for his scientific contributions through both academic and research-oriented accolades. Notably, he is the recipient of a research grant from the Xuzhou Municipal Health Commission (Project No. XWKYHT20230029), focusing on cerebral ischemia-reperfusion and blood-brain barrier injury. Though early in his professional career, his selection as Principal Investigator on this project signifies trust in his leadership and expertise. Several of his publications in high-impact journals list him as co-first author—an honor that highlights his equal contribution in rigorous experimental work. While he has yet to receive national awards such as from the Natural Science Foundation, his steady academic output and funded research projects mark a strong trajectory. His growing publication record and role in significant studies position him as a rising talent in the biomedical field. Future honors are likely as his research continues to address key questions in neuroscience and pharmacology.

🔬 Research Focus:

Zhaowei Feng’s research centers on neuroprotection, demyelination, and neuroinflammation, with a particular focus on the mechanisms underlying multiple sclerosis, ischemic brain injury, and neonatal encephalopathy. His studies often employ animal models such as cuprizone-induced demyelination and hypoxia-ischemia to explore therapeutic targets. Feng is particularly interested in the regulation of oligodendrocyte differentiation and the role of glutamate transporters, signaling molecules like PPARγ, and pathways involving Wnt/β-catenin and SUMOylation. Additionally, he has investigated compounds such as diosgenin and alpha-asaronol for their neuroprotective and remyelination-promoting effects. His work also extends into cancer biology, with studies on ferroptosis and protein regulation in squamous cell carcinoma. By integrating molecular biology, pharmacology, and neurodevelopmental research, Feng aims to contribute to the discovery of new treatments for central nervous system disorders. His current and future research is geared toward translational medicine that bridges laboratory science with clinical applications.

📚 Publication Top Notes:

  1. 🧠 Alpha-Asaronol Alleviates Dysmyelination by Enhancing Glutamate Transport via PPARγ-GLT-1 Signaling in Neonatal Hypoxia-Ischemia (Pharmacology, 2022)

  2. 🧬 C1q Inhibits Differentiation of Oligodendrocyte Progenitor Cells via Wnt/β-Catenin Signaling (Biomedicine & Pharmacotherapy, 2023)

  3. 🧪 Alpha-Asaronol Promoted OPC Differentiation and Improved Myelination as a PPARγ Activator (Frontiers, 2023)

  4. 🧫 Diosgenin Promoted OPC Differentiation by Blocking GLUR2/GAPDH Interaction in Pilocarpine-Induced Epilepsy Rats (Phytomedicine, 2025)

  5. 🧬 Netrin-4 Mediates Piezo1 Inactivation and YAP Signaling Alleviation in Cerebral Ischemia-Reperfusion (Oncology Reports)

  6. 🔬 SENP1 Inhibits Ferroptosis and Promotes Head and Neck Squamous Cell Carcinoma by Regulating ACSL4 Protein (Molecular Oncology, 2023)

  7. 🧪 SUMO1-Mediated Stabilization Enhances Protein Function in Neuroinflammatory Models (Unspecified Journal)

  8. 🧠 Signaling Activation in a Cuprizone-Induced Mouse Model of Multiple Sclerosis (Unspecified Journal)

📌 Conclusion:

Zhaowei Feng is a highly promising early-career researcher with a clear scientific focus, a growing publication record, and demonstrated ability to lead independent research. His work addresses critical challenges in neurobiology and pharmacology, making a tangible impact in both experimental and translational medicine. With continued progression—especially toward national-level recognition and senior authorship—he has the potential to become a leader in his field.